Stock Events

Stock Events

Nanobiotix 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 5NRA.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biotech company that develops innovative therapies, including for cancer, which competes with Nanobiotix's focus on nanomedicine for oncology.
Merck
MRK
Mkt Cap298.84B
Merck is a global healthcare company that produces cancer treatments, directly competing with Nanobiotix's cancer-focused nanotherapeutics.
Novartis
NVS
Mkt Cap297.32B
Novartis is involved in the research and development of novel healthcare solutions, including cancer treatments, making it a competitor in the oncology space.
Pfizer
PFE
Mkt Cap161.09B
Pfizer develops and manufactures drugs and vaccines, including for cancer, competing with Nanobiotix's oncology innovations.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences is a biopharmaceutical company that develops cancer therapies, competing with Nanobiotix's approach to cancer treatment.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb is a global biopharmaceutical company focusing on cancer drugs, competing with Nanobiotix's cancer treatment technologies.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals focuses on developing biopharmaceutical treatments, including for cancer, making it a competitor to Nanobiotix.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals engages in creating new therapies, including for serious diseases potentially overlapping with Nanobiotix's target areas.

About

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Show more...
CEO
Mr. Laurent Levy Ph.D.
Employees
103
Country
Germany
ISIN
US63009J1079

Listings

STU
DE
5NR.STU
MU
DE
5NR.MU
STU
DE
5NRA.STU
MU
DE
5NRA.MU

0 Comments

Share your thoughts

FAQ

What is Nanobiotix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nanobiotix stocks are traded under the ticker 5NRA.MU.
How many employees does Nanobiotix have?▼
As of April 12, 2026, the company has 103 employees.
In which sector is Nanobiotix located?▼
Nanobiotix operates in the Health & Wellness sector.
When did Nanobiotix complete a stock split?▼
Nanobiotix has not had any recent stock splits.
Where is Nanobiotix headquartered?▼
Nanobiotix is headquartered in Paris, Germany.